Henry Schein Inc (HSIC)vsNovartis AG ADR (NVS)
HSIC
Henry Schein Inc
$84.95
+1.51%
HEALTHCARE · Cap: $9.43B
NVS
Novartis AG ADR
$155.41
+0.19%
HEALTHCARE · Cap: $296.54B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 323% more annual revenue ($56.58B vs $13.38B). NVS leads profitability with a 23.9% profit margin vs 3.0%. HSIC appears more attractively valued with a PEG of 1.82. HSIC earns a higher WallStSmart Score of 52/100 (C-).
HSIC
Buy52
out of 100
Grade: C-
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.6%
Fair Value
$152.96
Current Price
$84.95
$68.01 discount
Margin of Safety
-69.7%
Fair Value
$91.58
Current Price
$155.41
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.5% earnings growth
3.0% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : HSIC
The strongest argument for HSIC centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : HSIC
The primary concerns for HSIC are PEG Ratio, P/E Ratio, EPS Growth. Thin 3.0% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
HSIC profiles as a value stock while NVS is a declining play — different risk/reward profiles.
HSIC carries more volatility with a beta of 0.82 — expect wider price swings.
HSIC is growing revenue faster at 6.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
HSIC scores higher overall (52/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Henry Schein Inc
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?